Objective: This study was aimed to evaluate the economic benefits of clinical pharmacy service in hyperlipidaemic management in accordance to the ATP III guidelines. Methods: A clinical pharmacy service was developed at the lipid clinic of Prince of Wales Hospital (PWH) between October 2005 and October 2007. In the intervention group, patients attended educational visits conducted by a clinical pharmacist. Medication compliance and the proper use of drugs were assessed. Monthly telephone follow-ups were made to check on the progress of patients. The time spent by the pharmacist was recorded. In the control group, patients received usual medical care with no pharmacist intervention. Results: A total of 300 patients were recruited (150 in the intervention group and 150 in the control group). Intervention group achieved 23.6%, 15.3%, and 22.3% mean reduction in LDL-C, total cholesterol and triglyceride levels, respectively, compared with 3.7%, 5.2%, and 2.7% in the control group. A sustained reduction in total cholesterol of 1% is associated with a 2-3% reduction in CHD risk. Pharmacist conducted mean of 3.34 + 0.7 educational visits and 16.3 + 3.3 telephone follow-up calls. The overall time spent was 3.08 minutes per patient per week. The average monthly salary of a hospital pharmacist was HK$30,000 (HK$7.8 = USD$1). In previously published data, 0.39 patients per year at the PWH lipid clinic experienced acute myocardial infarction (AMI) and required HK$28,800 medical cost annually. Clinical pharmacy service reduced the CHD risk of these patients and prevented the development of an AMI, providing a potential cost saving of HK$28,600 (which was 99% cost reduction) per patient per year at PWH. (Estimated cost of pharmacist to manage 0.39 patients per year is HK$182.18). Conclusion: Clinical pharmacy service is potentially a cost-effective way to improve the management of hyperlipidaemia alongside with routine physician care.